HPTN Studies

Our studies strive to prevent HIV acquisition and transmission through the use of antiretroviral drugs, interventions for substance use, behavioral risk reduction, and structural interventions. 

HPTN research studies are developed by protocol teams that include CTU investigators and recognized experts in HIV prevention. As study protocols are developed, they undergo a rigorous intra- and extra-Network review process that ensures compliance with current ethical guidelines and regulatory procedures. Each Study Protocol is available once version 1.0 is approved and distributed to the performance sites.

 

Study Snapshot

Study Timelines

Filter studies by:

HPTN 075 (11943)

Feasibility of HIV Prevention Cohort Studies Among MSM in Sub-Saharan Africa

Concluded

Behavioral

HPTN 074 (11917)

Integrated Treatment and Prevention for People Who Inject Drugs: A Vanguard study for a Network-based Randomized HIV Prevention Trial Comparing an Integrated Intervention Including Supported Antiretroviral Therapy to the Standard of Care

Concluded

Treatment as Prevention

HPTN 071 (11865)

Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART): A cluster-randomized trial of the impact of a combination prevention package on population-level HIV incidence in Zambia and South Africa

Archived

Treatment as Prevention

HPTN 073 (11894)

Pre-Exposure Prophylaxis (PrEP) Initiation and Adherence among Black Men who have Sex with Men (BMSM) in Three U.S. Cities

Concluded

PrEP

HPTN 069 (11789)

A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir disoproxil fumarate (MVC+TDF), or Tenofovir disoproxil fumarate + Emtricitabine (TDF+FTC) for Pre-Exposure Prophylaxis (PrEP) to Prevent HIV Transmission in At-Risk Men Who Have Sex with Men and in At-Risk Women

Concluded

PrEP

HPTN 068 (11710)

Effects of cash transfer for the prevention of HIV in young South African women

Concluded

Structural

HPTN 067 (10852)

A Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate
Pre-Exposure Prophylaxis (PrEP)

Concluded

PrEP

HPTN 066 (10851)

Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate in Healthy Volunteers

Concluded

Antiretroviral Therapy